Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 1/2020

16.07.2019 | Case Report

Gastrointestinal Mantle Cell Lymphoma with Varied Findings

verfasst von: Atsushi Goto, Jun Nishikawa, Shunsuke Ito, Eizaburou Hideura, Tomohiro Shirasawa, Koichi Hamabe, Shinichi Hashimoto, Takeshi Okamoto, Isao Sakaida

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Mantle cell lymphoma (MCL) is a relatively rare B cell lymphoma characterized by overexpression of cyclin D1 associated with t(11;14) (q13;q32) translocation. It is diagnosed by the appearance of lymphocytes histopathologically positive for CD5, CD20, and cyclin D1 and detection of the t(11:14) translocation by genetic analysis. Gastrointestinal tract involvement is found in approximately 20 to 30% of MCL cases [16], and gastrointestinal symptoms and endoscopy may be the starting point for detecting MCL. Most MCLs are often found at advanced Ann Arbor classification stages of III/IV [7] and have a particularly poor prognosis among the B cell lymphomas. Early detection of gastrointestinal MCL is important for the initiation of early therapeutic intervention, but it is not easy to diagnose gastrointestinal MCL endoscopically because the macroscopic findings are diverse. Because it is essential for gastroenterologists to correctly understand the endoscopic image of gastrointestinal MCL, we describe our patient with MCL and review the relevant literature. …
Literatur
1.
Zurück zum Zitat Weisenburger DD, Armitage JO. Mantle cell lymphoma- an entity comes of age. Blood. 1996;87:4483–94.CrossRef Weisenburger DD, Armitage JO. Mantle cell lymphoma- an entity comes of age. Blood. 1996;87:4483–94.CrossRef
2.
Zurück zum Zitat Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia. 1997;11(Suppl 2):S60–4.PubMed Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia. 1997;11(Suppl 2):S60–4.PubMed
3.
Zurück zum Zitat Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol. 1997;15:1664–71.CrossRef Majlis A, Pugh WC, Rodriguez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol. 1997;15:1664–71.CrossRef
4.
Zurück zum Zitat Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567–75.CrossRef Bosch F, López-Guillermo A, Campo E, et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer. 1998;82:567–75.CrossRef
5.
Zurück zum Zitat Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253–61.PubMed Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253–61.PubMed
6.
Zurück zum Zitat Lamm W, Dolak W, Kiesewetter B, Simonitsch-Klupp I, Puhr H, Raderer M. Gastrointestinal involvement in patients with mantle cell lymphoma: a single center experience of eighty-five patients. Dig Dis. 2019;37:194–200.CrossRef Lamm W, Dolak W, Kiesewetter B, Simonitsch-Klupp I, Puhr H, Raderer M. Gastrointestinal involvement in patients with mantle cell lymphoma: a single center experience of eighty-five patients. Dig Dis. 2019;37:194–200.CrossRef
7.
Zurück zum Zitat Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791–8.CrossRef Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791–8.CrossRef
8.
Zurück zum Zitat Lymphoma Study Group of Japanese Pathologists. The World Health Organization Classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000;50:696–702. Lymphoma Study Group of Japanese Pathologists. The World Health Organization Classification of malignant lymphomas in japan: incidence of recently recognized entities. Lymphoma Study Group of Japanese Pathologists. Pathol Int 2000;50:696–702.
9.
Zurück zum Zitat Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, de Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15:517–25.CrossRef Belaud-Rotureau MA, Parrens M, Dubus P, Garroste JC, de Mascarel A, Merlio JP. A comparative analysis of FISH, RT-PCR, PCR, and immunohistochemistry for the diagnosis of mantle cell lymphomas. Mod Pathol. 2002;15:517–25.CrossRef
10.
Zurück zum Zitat Kodet R, Mrhalová M, Krsková L, Soukup J, Campr V, Neskudla T, et al. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch. 2003;442:538–47.CrossRef Kodet R, Mrhalová M, Krsková L, Soukup J, Campr V, Neskudla T, et al. Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. Virchows Arch. 2003;442:538–47.CrossRef
11.
Zurück zum Zitat Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer. 2013;119:1570–7.CrossRef Ambinder AJ, Shenoy PJ, Nastoupil LJ, Flowers CR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer. 2013;119:1570–7.CrossRef
12.
Zurück zum Zitat Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97:586–91.CrossRef Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97:586–91.CrossRef
13.
Zurück zum Zitat Hou WH, Wei P, Xie JL, et al. Clinicopathologic features and prognosis of gastrointestinal mantle cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 2018;47:763–8.PubMed Hou WH, Wei P, Xie JL, et al. Clinicopathologic features and prognosis of gastrointestinal mantle cell lymphoma. Zhonghua Bing Li Xue Za Zhi. 2018;47:763–8.PubMed
14.
Zurück zum Zitat Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T, et al. Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol. 2010;16:4661–9.CrossRef Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T, et al. Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol. 2010;16:4661–9.CrossRef
15.
Zurück zum Zitat Cornes JS. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer. 1961;14:249–57.CrossRef Cornes JS. Multiple lymphomatous polyposis of the gastrointestinal tract. Cancer. 1961;14:249–57.CrossRef
16.
Zurück zum Zitat Kodama T, Ohshima K, Nomura K, Taniwaki M, Nakamura N, Nakamura S, et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology. 2005;47:467–78.CrossRef Kodama T, Ohshima K, Nomura K, Taniwaki M, Nakamura N, Nakamura S, et al. Lymphomatous polyposis of the gastrointestinal tract, including mantle cell lymphoma, follicular lymphoma and mucosa-associated lymphoid tissue lymphoma. Histopathology. 2005;47:467–78.CrossRef
17.
Zurück zum Zitat Tamura S, Ohkawauchi K, Yokoyama Y, Higashidani Y, Daibata M, Hiroi M, et al. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract. J Gastroenterol. 2004;39:995–1000.CrossRef Tamura S, Ohkawauchi K, Yokoyama Y, Higashidani Y, Daibata M, Hiroi M, et al. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract. J Gastroenterol. 2004;39:995–1000.CrossRef
Metadaten
Titel
Gastrointestinal Mantle Cell Lymphoma with Varied Findings
verfasst von
Atsushi Goto
Jun Nishikawa
Shunsuke Ito
Eizaburou Hideura
Tomohiro Shirasawa
Koichi Hamabe
Shinichi Hashimoto
Takeshi Okamoto
Isao Sakaida
Publikationsdatum
16.07.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 1/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00277-y

Weitere Artikel der Ausgabe 1/2020

Journal of Gastrointestinal Cancer 1/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.